Invion Limited

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:21:25 2024-05-16 am EDT 5-day change 1st Jan Change
0.0055 AUD +10.00% Intraday chart for Invion Limited +10.00% +10.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Invion Partners with Hanlim Pharma for Glioblastoma Treatment MT
Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results MT
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Invion Signs Collaboration Agreement with Dr. I&B Co for HPV Treatment; Shares Up 25% MT
Invion Nears Clinical Trial of Cancer Photodynamic Therapy with Drug Substance Production MT
Invion Grants RMW Cho Group Right to Distribute Cancer Treatment Products in South Korea MT
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Invion Launches New Interactive Investor Hub MT
Invion Limited agreed to acquire Next Generation Photodynamic Therapy of RMW Cho Group Limited. CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Invion Expanding Photosoft Technology Rights to US, Canada, Hong Kong MT
Invion Limited Announces Vitro Test Results on Photosoft CI
Invion Limited Announces the Positive Screening Results from in Vitro Studies of PhotosoftTM on the Inhibition of the Dengue Virus CI
Invion Validates Efficacy of Photodynamic Drug Against Anal Cancer MT
Invion Limited Announces INV043 Effective Against Anal Cancer Squamous Cell Carcinomas in Vitro CI
Invion Limited Announces PhotosoftTM Shows Activity Against Zika Virus in Preliminary Assays CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Invion's Cancer Treatment Patent Application Published MT
Invion Limited Announces International Patent to Extend IP Protection for Photosoft CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Invion Limited Announces Company Secretary Changes CI
Invion's Cancer Drug Regresses Tumor, Triggers Immune Response in Animal Study; Shares Surge 131% MT
Invion Limited Announces INV043 Shown to Completely Regress TNBC Tumours and Trigger Protective Immunity CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2021 CI
Invion Limited Auditor Raises 'Going Concern' Doubt CI
Chart Invion Limited
More charts
Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
More about the company
  1. Stock Market
  2. Equities
  3. IVX Stock
  4. News Invion Limited
  5. Invion Partners with Hanlim Pharma for Glioblastoma Treatment
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW